|Mr. Qingming Yu||Exec. Chairman||1,07M||N/A||1964|
|Mr. Yong Liu||Pres & Exec. Director||1,04M||N/A||1969|
|Mr. Xiuchang Jiang||CFO & VP||N/A||N/A||1964|
|Ms. Xiaojuan Li||Chief Financial Officer||N/A||N/A||1976|
|Mr. Yijian Wu||Company Sec.||N/A||N/A||1970|
|Mr. Wanyong Lian||VP||N/A||N/A||1971|
|Mr. Shuangjun Xu||Non-Exec. VP||N/A||N/A||1969|
|Mr. Maisong Cai||VP||N/A||N/A||1970|
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.
O QualityScore de governança da ISS da Sinopharm Group Co., Ltd. a partir de 26 de setembro de 2021 é 10. As principais pontuações para Auditoria são: 2; Conselho: 10; Direitos de Acionistas: 10; Compensação: 9.